BRAF and metastatic melanoma: Recent advances in molecular profiling of tumors and immunotherapy have led to the development of new FDA-approved agents for metastatic melanoma, including the immune-checkpoint inhibitor, ipilimumab (34), and the BRAF inhibitor, vemurafenib (35).